Pay in 4 interest-free payments of $6.71 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Frequently Asked Questions About AOD-9604 Safety How many people have been studied in AOD-9604 clinical trials
By increasing NAD levels and activating the SIRT1 pathway, NNMTi inhibits the activation of inflammatory signaling pathways (such as the NFB pathway), thereby reducing macrophage infiltration and inflammatory factor release
A typical dose is about 1,000 mcg a day
AOD-9604, a synthetic fragment derived from the C-terminal region of human growth hormone, has been subjected to extensive clinical evaluation involving over 900 participants across six randomized controlled trials
The 2024 NICE guideline on B12 deficiency in over-16s is built around identifying and treating the cause, not just topping up the number
These injections offer a direct and efficient way to replenish the bodys B12 levels, which are essential for overall well-being
